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Summary:  
 
Typically, clinical trials compare a new product or therapy with another that already exists to 
determine if the new one is as successful as, or better than, the existing one. In some studies, 
participants may be assigned to receive a placebo. Comparing a new product with a placebo 
can be the fastest and most reliable way to demonstrate the new product’s therapeutic 
effectiveness. However, placebos are not used if a patient would be put at risk, particularly in 
the study of treatments for serious illnesses by not having effective therapy. Most of non-
inferiority studies compare new products with an approved therapy. The active-controlled trial 
with a non-inferiority design has gained popularity in recent years. They have methodological 
challenges, especially in determining the non-inferiority margin. Regulatory guidelines 
provide some general statements on how an NI trial should be conducted. In this narrative 
review based on scientific literature and papers, but also publications about clinical trials, we 
will define NI trial concepts, explain the main methodology of NI margin determination with 
its limitations and the potential margin of improvement. 
 
 
Key words: randomized controlled trial, non-inferiority, active-control, non-inferiority margin 
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1. Introduction 
1.1 Generalities about clinical trial 
A clinical trial is an interventional research on a human subject. They are designed to answer 
specific questions about biomedical or behavioral interventions, including new treatments 
such as novel vaccines or drugs. (1) Clinical trials are the gold standard in order to confirm 
drug efficacy. They allow rigorous scientific evaluation of treatment strategies and validation 
of patient care. Considering  the complexity of pathophysiology, pharmacology, the 
probabilistic outcome in medicine, and because of bias in observational studies, it makes 
clinical trials the rational basis for physicians to provide credible evidence and draw 
information used to adapt their therapeutic practice. 
 
        1.2 Randomization and blinding 
Randomization is the process by which two or more alternative treatments are assigned to 
volunteers by chance rather than by choice. This is done to avoid any bias with investigators 
assigning volunteers to one group or another.  The results of each treatment are compared at 
specific points during a trial, which may last for years. When one treatment is found superior, 
the trial is stopped so that the fewest volunteers receive the less beneficial treatment. RCT are 
almost always defined as single or double blinded trials. Blind studies are designed to prevent 
members of the research team or study participants from influencing the results. Indeed, the 
participants do not know which medicine is being used . This allows scientifically accurate 
conclusions. In single-blind studies, only the patient is not told what is being administered. 
In a double-blind study, only the pharmacist knows; members of the research team are not 
told which patients are getting which medication, so that their observations will not be biased. 
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If medically necessary, however, it is always possible to find out what the patient is taking. 
(2) 
When the aim of the randomized controlled trial (RCT) is to show that the one treatment is 
superior to another the test is called a superiority trial and the associated statistical test is a 
superiority test. A non significant superiority test is often mistaken as a proof that two 
treatments are not different. But proving that two treatments are equal is impossible with 
statistical tools. The closest possibility is to prove that two treatments are equivalent, meaning 
are not too different in characteristics, where ‘not too different’ is defined in a clinical matter.  
 
        1.3 Introduction to NI trials 
Relative to development of medical treatments, it is becoming increasingly difficult to 
develop more powerful drugs, thusly the pharmaceutical companies are looking for treatments 
that have approximately the same efficacy, or a little worse, but demonstrate better qualities in 
other aspect. This type of RCTs aims to show that an experimental treatment is not inferior to 
the control treatment. Such trials are called non-inferiority trials. (3) The concept of NI trials 
started in 1970, based on the methodology of bioequivalence trials. In some circumstances, 
for example trials involving serious outcomes such as mortality, it is unethical to assign 
patients to a placebo. The term ‘active control trial’ refers to trials in which the control 
treatment employed is an active one. Most NI trials are using active control that is why they 
became increasingly popular in 1990s after the introduction of regulatory guidelines about the 
use of active- controlled trials. This is shown by a major increase of publications on NI trials 
since the first guideline. (4) A research on Pubmed including the terms ‘non-inferiority’, with 
‘randomized controlled trial’ and ‘humans’ not ‘bioequivalent’ revealed only 1 publication in 
1998 and the number increased to 189 in 2015, with a peek level in 2014 of 230 publications. 
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Table 1: Pubmed research [(non-inferior) or (noninferior) and (randomized controlled trial) 
and (humans) not (bioequivalence)] http://ncbi.nlm.nih.gov accessed april 2016. 
Year Count 
2016 (not complete) 11  
2015 189 
2014 230 
2013 205 
2012 187 
2011 146 
2010 122 
2009 108 
2008 84 
2007 58 
2006 44 
2005 30 
2004 14 
2003 10 
2002 7 
2001 2 
2000 2 
1999 1 
1998 1 
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 This illustrates the growing interest in NI trials as well as the increased need for readers and 
clinicians to understand the concept of this methodology.  
First we will start by describing where NI stands with the general process of drug 
development, from its discovery until commercialization. In order to understand details about 
NI trials methodology we will explain in a second time what the different types of trial are 
and what are their differences. After the review of methodological and statistical concepts of 
NI margin we will discuss the quality of non-inferiority trials. 
 
2. General overview of the regulatory clinical drug 
development 
 
[ figure 1: Drug DevelopmentvProcess . 
www.roche.com/understanding_clinical_trials.pdf accessed May 2016]. 
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Research and development aims to prevent and treat disease. The end result a small capsule 
seems so simple but the process for developing a new drug is anything but that. Development 
can take up to 20 years and cost 1 billion dollars. Several stages and team work involving the 
government, universities and pharmaceutical companies are required to reach the finish line. 
 
        2.1 Discovery and development 
Research for a new drug begins in the laboratory. National Institute of Health, labs around the 
world work to discover fundamental knowledge about diseases. They aim to identify drug 
targets, mostly genes and proteins that play a crucial role in development or appearance of a 
disease. Scientists then investigate on how they interfere with these targets to control and 
eliminate a disease. They test thousands of compounds to see if they have an effect, but very 
small part will turn out to really have one. After the list of potential drug candidates is done, 
research on absorption, distribution and metabolism of the compound starts. Once researchers 
identify a promising compound for development they conduct experiments to gather 
information on potential benefits and mechanisms of action, best dosages, side effects, how it 
affects different groups of people and how it interacts with other drugs. 
 
     2.2 Pre-clinical stage 
Researchers must find out if the drug has potential to be dangerous before testing a drug on 
people. They are two types of pre-clinical research: in vitro and in vivo. The new compound 
undergoes laboratory and animal testing to answer basic question about safety. 
GLP which stands for ‘Good Laboratory Practices’ are required by FDA and are defined in 
medical product development regulations. They set basic requirements for study conduct, 
personnel, facilities, equipment, written protocols, operating procedure, study reports and a 
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system of quality assurance oversight for each study to help assure the safety of FDA-
regulated product. (5) Pre-clinical studies are usually not very large. Nevertheless, they must 
provide detailed information on toxicity levels and doses. If the results are encouraging, the 
principal investigators will apply for an approval to start clinical experiments. Those 
approvals are issued by special governmental agencies, such as European Agency for the 
Evaluation of Medical Products and US FDA. After these pre-clinical tests, researchers decide 
which compound is safe for further testing on people. Pre-clinical research is necessary but is 
not a substitute for studies on how drugs interact in a human body. 
 
 
        2.3. Clinical phases 
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[Figure 2 : A flow diagram to show the different phases in a clinical trial. 
www.yourgenome.org  accessed May 2016] 
Clinical research, also called trials, refer to studies on people which make sure they are safe 
and effective. Before starting the tests, researchers must design the trial, so it follows a 
specific protocol. They have to decide who will participate, how people will be part of the 
study, how long will the studies last, decide on a control group, drug administration, which 
data will be collected and how it will be analyzed.  Before starting clinical research, drug 
developers must submit an ‘Investigational New Drug’ (IND) application to FDA, 
including animal study data and toxicity, manufacturing information, clinical protocols, data 
from any prior human research and information about the investigator.  The FDA team that 
consists of a statistician, pharmacologist, medical officer, project manager, pharmakineticist, 
chemist and microbiologist has 30 days to review the IND submission. They can either 
approve the beginning of a trial or place a clinical hold if the participants are exposed to 
significant risk, if the investigators are not qualified, or if the IND application lacks 
information about the risks. 
Clinical trial has 3 phases. The first phase or ‘safety’ is a small trial usually enrolls 20 to 100 
healthy volunteers. During the first phase, researchers want to determine if a potential drug 
is safe for human use, and which doses can be tolerated by a human organism. Also 
pharmacokinetics is being carefully monitored as well as side effects.  
Phase two ‘protocol’ involves 50 to 500 people with the disease that is to be treated with a 
potential drug. The purpose of that phase is to determine its effectiveness and to further 
evaluate its safety. In other words, investigators would like to know if treatment works well 
enough to be tested in larger phase 3 trials, as well as the sample size needed for the final 
phase, optimal dose, and optimal treatment protocol. (6) Side effects are also studied, 
although they were tested in phase 1, there might be some more that doctors didn’t know 
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about. 
Phases three are randomized controlled trials on larger patient groups, from 300 to 3000 
volunteers who have the disease. They aim to confirm previous findings, especially drug 
effectiveness, by comparing it with standard or equivalent treatments and collect 
information that will allow the experimental drug or treatment to be used safely. The decision 
to move ahead with this study is major one because the costs are considerably higher than for 
the two earlier phases combined. A drug identified as effective and safe in phase 2 may not 
enter phase 3 for a number of reasons. If it has insufficient efficacy when compared with its 
competitors, or when the side effects exceed the risk profile required to proceed.(7) 
This phase represents a critical part of a drug’s clinical testing cycle and is the one that we 
will focus on because NI trials play a major role here. The results of this phase will show 
the FDA investors and doctors if the drug really works. 
 
        2.4.FDA review and pharmacovigilance 
When a drug is satisfactory after phase three, the company can file an application to market 
the drug. It is called a NDA: New Drug Application. NDA tells the full story of the drug in 
order to show that it is safe and effective. The NDA must include all information from pre-
clinical to phase 3 along with proposed labeling, safety updates, information about drug 
abuse, patient information, any data from outside study and directions for use. If it is not 
complete the FDA will refuse the NDA. The review team has 6 to 10 months to make a 
decision. Each member will review the application concerning his section. The inspector will 
travel to the study site for inspection. In the end the manager will assemble all documents in 
order to create the record for FDA review. Complete information on drug safety is impossible 
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despite rigorous steps in process of drug development. FDA reviews report can decide to add 
cautious about dosage or usage if reviews report problems with prescription.  
Phase 4 clinical trial represents a post marketing surveillance trial, also called 
pharmacovigilance. These ongoing reviews of drugs are required by regulatory authorities or 
sponsoring companies for competitive reasons. The goal of pharmacovigilance is to detect 
complications, long term side effects that were not described during phases 1 to 3 trials. In 
that case the drug will be taken out of the market. 
 
3. Three types of hypothesis tested in clinical trials 
RCT are essential to assess and compare the effectiveness of treatments. Superiority testing 
are typically used in comparative trials. However, superiority is getting more difficult to 
show, and becomes less important as margins of improvement decrease to clinically irrelevant 
levels. Alternative methods to compare groups in RCT are equivalence and non-inferiority. 
(8) 
 
        3.1 Inequality trials 
                3.1.1 Definitions 
Inequality trials, also called superiority trials started in 1900s, while William Gosset 
encountered the problem of having to find the best barley to brew Guinness beer. (9) His work 
led the way for the establishment of two indices related to superiority testing: p values and 
confidence intervals. P value is the probability that the differences observed between two or 
more groups occurred by chance if there really was no difference between the groups, usually 
set at 5% as a threshold. .Whereas the confidence interval represents the interval around an 
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observed parameter guaranteed to include the true value to some level of confidence. The true 
value can be expected to be within that interval with 95% confidence. (10) The CI should not 
include 0 for continuous values or 1 for ratios, both of which are consistent with no 
difference.   
 
                3.1.2 Superiority trial : looking for better 
A superiority trial aims to demonstrate the superiority of a new treatment compared to an 
established therapy or placebo. Its means that the outcome of the patient after receiving the 
medication is better than with the old one, or with placebo. It can be for example decreased 
risk of clot with anti-coagulant therapy, a better surgical procedure with smaller amount of 
blood loss, etc. The goal of this type of trial is to test if the hypothesis of superiority is true or 
not. In order to do so, the first step in a superiority trial is to set the null hypothesis called Ho, 
in opposition with the alternative hypothesis (Ha) that we are trying to prove. The null 
hypothesis states that there is no association between the predictor and outcome values. In 
other words appropriate statistical tests needed to assess superiority should be performed, with 
the null hypothesis being: the difference between treatments is equal to zero, and the 
alternative hypothesis: treatment are different, the difference between treatments is not equal 
to zero. The rejection of the null hypothesis is in foundation of the methodological assessment 
of superiority. (11) The extra effect of the new therapy compared to the reference therapy is 
called the Least Relevant Difference, often written as delta.  
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[Figure 3: diagram illustrating the principle of superiority testing. The effects of an active 
control and a new treatment are given as 95% CIs of the difference between treatments, 
measured along the x-axis. DELTA 0 line represents a least relevant difference between 
groups of 0. (8)] 
 
We can see that trial n°1 confidence interval includes zero so there is no difference 
between groups. Trial n°2 lies below zero line of less favorable outcome, implying a 
significantly worse, inferior result than the treatment is it compared to. Trial n°3 is 
significantly better, superior results, show by a 95% CI that lies entirely on the favorable 
side. Furthermore, the CI is shorter than with treatment n°4, therefore the differences 
between treatments in trial n°3 are more precise than in n°4, which also shows superiority.  
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                3.1.3 Type 1 and 2 errors, limitations 
The trial should demonstrate as precisely as possible the true difference in effects between 
treatments. However, the result may deviate from the true difference and give erroneous 
results because of the random variation. For example if the null hypothesis H0 were true, it is 
still possible that the trial in some case would show a difference. This is called type 1 “false 
positive” error, which would introduce an ineffective therapy. On the other hand if the 
alternative hypothesis of the delta difference were true, the trial can fail to demonstrate a 
difference. This type of error is called type 2 “false negative”, and rejects an effective 
therapy. This is why the investigator needs to specify how large risks of type 1 and type 2 
errors would be acceptable for the trial. Because of limitation in patient number and resource, 
some small risk in error is tolerated. Most often type 1 error, that occurs with probability 
alpha,  is specified to 5% and type 2 error that occurs with probability beta, 10 to 20%. 1 – 
beta is power, the probability of saying that there is a relationship or difference when there is 
one. It is the probability of confirming the theory correctly, so a trial designer would generally 
want this to be as large as possible in order to be confident in detecting a hypothesized 
difference in treatment effects. (12) 
Superiority trials have been the standard for some time, but the success of new drugs that are 
always better than the previous ones creates a ceiling effect. That is why equivalence and non-
inferiority trials are very useful when the superiority of one medication over another is neither 
expected or worse than the comparator. In general, superiority trials are used when new 
advances in treatment therapy, or effect of active control is small.  
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        3.2 Equivalence trials 
                 3.2.1 Pharmaceutical, clinical and bioequivalence 
Most of the methodology of equivalence trials comes from studies of pharmaceutical 
bioequivalence. Drug products are defined as bioequivalent if they display comparable 
bioavailability, or absorbed percentage available at action site, when studied under similar 
experimental conditions. For drug products to be considered pharmaceutical equivalents 
they need to contain the same active ingredients, the same dosage form, route of 
administration and are identical in strength or concentration. Also they are formulated to 
contain the same amount of active ingredient in the same dosage form and to meet the same 
applicable standards: strength, quality, purity and identity. They may differ in characteristics 
such as shape, configuration, release mechanisms, packaging, excipients including colors, 
flavors, preservatives, expiration time, and, with certain limits, labeling. (13) We can say that 
pharmaceutical equivalence is a theoretical equivalence. On the other hand, therapeutic 
equivalence can be defined as “practical equivalence”. Firstly the drugs need to be 
pharmaceutical equivalent but also are expected to have the same clinical effect and safety 
profile when administered to patients. In other words, pharmaceutical equivalent that have 
been shown to be bioequivalent and the same by other determinations of clinical effect and 
safety profile are therapeutic equivalents. Therapeutic equivalents are then expected to 
produce identical drug concentration time profiles and therapeutic response when 
administered under the same conditions. As an example, a new nasal anti-congesting drug that 
is equivalent to the standard one would have to contain the same active ingredient (either 
pseudoephedrine or phenylephrine ) to be pharmacologically equivalent, but also clinically 
interchangeable and lessen the mucous membrane secretions and open the airway as much as 
the standard one.  
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                3.2.2 Equivalence margin definition 
“As much as” is defined as equivalence margin including lower and upper limits, we say that 
equivalence testing is a two-sided test. An equivalent margin is estimated and added to 
either side of the active treatment, and the effect of the new treatment is tested against this 
range. 
 
[Figure 4: The effects of an active control and a new treatment are given. The grey area is the 
equivalence margin. Only treatment 1 lies within the equivalent margin and is equivalent to 
the new treatment. (8)] 
A new treatment is equivalent only if it is no better and no worse, both within a margin (delta) 
than the active control. (8 ) This true two-sided equivalence approach is more common in 
pharmacokinetics, in which a difference in either direction from the reference treatment is of 
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importance. Whereas non-inferiority approach is much more common for therapeutic or 
prophylactic trials. (14) The value and impact of the study depend on how well the 
equivalence margin can be justified in terms of relevant evidence and clinical considerations. 
Regulatory issues have to be considered also. It is usually based on the margin of superiority 
of the standard treatment against placebo, estimated from previous studies. It must be stressed 
that this value should be determined before the data is recorded. This is essential to maintain 
the type 1 error at the desired level.  
 
                3.2.3 Equivalence after insignificant superiority? 
Also, it is not possible to conclude on equivalence if superiority failed to be demonstrated. On 
one hand the alternative and null hypothesis were not defined in the same manner. The 
alternative hypothesis intended to show a difference. A non significant result only implies that 
equality cannot be ruled out. On the other hand, the margin of equivalence is not considered 
and previously defined, so the concept of equivalence is not well defined. (15)  It is often 
though that equivalence is better than non-inferiority, because of the positive ring of being the 
same rather than non inferior, but this actually inverts the real situation where a non-
inferiority treatment has potential for superiority, whereas an equivalent treatment, by 
definition, cannot be better than the active control. 
         3.3 Non inferiority trials 
                 3.3.1 Active control instead of placebo 
The use of RCT designed to directly compare a test treatment and placebo is the most 
straightforward strategy to discriminate between effective and ineffective therapy. However, 
such a trial is not always a viable clinical development pathway for ethical reasons. 
Withholding an effective drug from a patient by using a placebo may lead to serious 
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complications or death. (16) The alternative is to compare the test treatment with an 
efficacious standard or active control treatment and demonstrate that the test is not inferior 
to the active control by a pre-determined margin instead of directly showing the superiority of 
the test treatment over placebo. The non-inferiority becomes the goal of the trial. (17) 
 
                 3.3.2 Superiority in secondary end points 
NI trials are used when the new treatment has technical similarities with the existing, or if the 
active control has moderate to significant effect, or specific safety problems. Another reason 
for choosing non-inferiority over superiority designs is that a new treatment may not be better 
in the primary end point but better in secondary end points. The new design may be 
designed to be safer with fewer complications or at least less severe. Not only side effects of 
treatment such as nausea, vomiting, headaches can be improved, but also for example the pain 
duration after an intervention is crucial for the patient. Of course less pain after surgery can’t 
outweigh the primary end points of the surgery in itself, but might be a strong argument. (8) 
When we talk about secondary end points, it can also be the overall efficiency. The cost of a 
treatment is not negligible. A treatment that is less expensive is more desirable. Given the 
strong and strongly growing emphasis on value-based healthcare and cost-effectiveness, these 
are important findings and might be included in some form in society guidelines and health 
policy regulations in the near future. 
                3.3.3. Superior is also non-inferior 
Non-inferiority testing is desirable as it also allows the potential to establish that it is better. 
Non-inferiority assessment is one-sided testing, meaning that it does not allow the possibility 
that the new treatment is worse (with a NI margin) than the active control, but better is also 
non-inferior, and non-inferiority testing does not exclude establishing superiority. NI 
testing can be complemented by superiority testing in one study without the need for adjusting 
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for multiple testing or loss of power of validity. The reciprocal is however not true. If the 
trial fails to show that it is superior and that there is a significant difference it doesn’t mean 
that there is no difference at all. It might be that the power of the trial wasn’t strong enough 
to show this difference between two treatments, or that the sample population was too small. 
In NI studies, the alternative hypothesis is that the experiment therapy is inferior to the 
standard therapy. This comes from a null hypothesis that stated that the experimental 
treatment is equal to or better than the control treatment. As we saw previously the alternative 
and null hypothesis of superiority testing are different, so the experimental method is not 
adequate. The prerequisite for NI trials also are more demanding than superiority. They 
require much larger sample sizes than superiority studies because the typical sizes of the 
anticipated margin in NI trials are much smaller than what would be considered a clinically 
meaningful difference between groups in superiority studies. 
                 3.3.4. Non-inferiority margin definition 
A non-inferiority trial starts with defining “no worse (within a margin)” or non-inferior before 
the beginning of the trial.  
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[Figure 5: diagram illustrating the principle of non-inferiority testing comparing a new 
treatment with an active control. An a priori defined NI margin (NIM) is added to the line of 
zero difference between treatments delta 0. (8)] 
 
 This requires the definition of an outcome and a threshold in that outcome, below which one 
would consider a new treatment to be inferior to an older one. (8) The modeling objectives of 
a NI trial can be classified into two categories, depending on whether or not placebo was used 
as a comparator in RCT in the past. When direct comparisons between placebo and active 
control are present in the historical trials, the ultimate goal is to predict the effect of the test 
treatment over placebo, or equivalently, determine the probability that the test treatment is 
better than the placebo as if the placebo is included in the NI trial. On the other hand, when 
only direct comparison among active control treatments are available, one needs to show that 
the test treatment is not inferior to the active control with a pre-specified margin. (16) This 
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margin should be determined during the design stage of a study before the actual experiment. 
Choosing the size of the margin is complex, and there is no explicit rule. This is one of the 
most difficult parts of the trial. How much efficiency on the result, such as mortality outcome, 
can we lose to get a better overall result, general status of the patient? The answer is very 
debatable. Usually findings from earlier studies and estimates of clinically relevant 
differences are combined. We will discuss later how it is determined in theory. 
                3.3.5 Biocreep 
After a NI trial, a new therapy may be accepted as effective, even if its treatment effect is 
slightly smaller than the current standard. It is therefore possible that, after a series of trial 
where the new therapy is slightly worse than the preceding drugs, an ineffective or harmful 
therapy might be incorrectly declared efficacious; this is known as ‘biocreep’. Several factors 
may influence the rate at which biocreep occurs, including the distribution of the effects of the 
new agents being tested and how they change over time, the choice of the active comparator, 
and changes in the effect of the active comparator from one trial to the next. (17) For 
example, if we accept that the new treatment B is not worse than 5%  to the standard one A, 
and then comparing an even newer treatment C with treatment B again by 5% with treatment 
C, and then treatment D with C and so on. Although the NI margin of 5% has never been 
violated in individual comparisons, treatment Z is far from the effect of the original treatment 
A. The definition and use of such a margin might seem arbitrary to some, but it actually is 
more rigorous than a superiority design because it involves a predefined minimum difference 
and statistical testing for the specific difference, whereas superiority trials assess only the 
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significance but not the size of a difference.  
 
[Figure 6:  The reiterative use of non-inferior treatments as new active controls for the next 
study levels to an overall reduction of effectiveness from treatments 1 to 5 although the non-
inferiority threshold was never violated in individual studies. The effect of placebo treatment 
is lower than the effect in the first, second, and third non-inferiority studies, but by the time of 
the fourth study, the non-inferiority threshold has crept to levels consistent with placebo 
treatment. (8)] 
To put it in a nutshell, comparison of a new treatment with an active control rather than 
placebo, establishment of a new treatment with better secondary outcomes, or as the first step 
in testing superiority of a new treatment,  all are reasons showing why NI trial are getting 
more important nowadays. Nevertheless, there is a potential weakness in NI testing, with 
possibility to flood the healthcare market with ‘me too’ procedures and products (18) that are 
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non-inferior than gold standard but do not add additional value, and risk of biocreep which 
highlight the fact that methodological rigor is even more important in NI than superiority test. 
 
4. Main points about non-inferiority trials 
        4.1 Bias  
In statistics bias means ‘a tendency of an estimate to deviate in one direction from a true 
value.’ (19) This systematic deviation from the true value can result in either underestimation 
or overestimation of the effects of an intervention. Because there is usually more interest in 
showing that a new intervention works than in showing that it does not work, biases in clinical 
trials most often lead to an exaggerate in the magnitude or importance of the effects of new 
interventions. The true effects of any health care intervention are unknown. But researchers 
try to anticipate, detect, quantify, and control bias to produce results from a sample of 
participants that can be generalized to the target population at large. Most bias occur during 
the actual course of a trial, from the allocation of participants to study groups, through the 
delivery of interventions, to the measurement of outcomes. Other types of bias can arise, 
however, even before the trial is carried out, in the choice of problem to study or type of 
research to use, or after the trial is carried out, in its analysis, and its publication. Bias can 
even be introduced by the person who is reading the report of a trial. (20) Some strategies 
must be settled to prevent as much as possible these errors that will eventually lead to a 
deviation of inferences or results from the truth. The study must be prospective, meaning that 
the population sample, strategy plan, criteria for judgment, margins, all had to be set before 
the start of the trial. The use of a control group, receiving placebo or standard treatment is 
also essential in order to assure the quality of the trial inference. (21) If for example the study 
on a new treatment for grasses allergy as 100% of cure, we will conclude on very high 
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efficacy. But if the the control group also shows the same results, then the conclusion will be 
different. A lot of external factors can create effects that can be confused with the effects of 
the treatment studied. Natural evolution of the disease, placebo effect, or the existence of 
concomitant treatment are a few examples. Only the use of control group can prevent 
inclusion of these confounders, defined as ‘a variable that is related to both the exposure and 
outcome but is not measured or is not distributed equally between groups.’ (22) So that the 
results showed in the study are only linked with the treatment given, the different groups 
should be chosen on the exact same basic criteria such as age, sex, height and weight, but also 
on the severity of the disease and should differ only on the treatment received. As we saw in 
the introduction, randomization is the only way for the groups to be truly comparable. Any 
other method would introduce a selection bias. The method in practice is done by a computer 
generating random numbers assigned to each patient corresponding to which treatment they 
will follow. (23). The randomization must be kept throughout the study. In order to do so, the 
patient and the researcher can’t know the nature of the treatment. This is what we call a 
double-blinded study. Otherwise, follow-up bias may be introduced. It can be a modification 
in rhythm of visits to the patient, how well the examination will be performed and side-effect. 
Even unconsciously the researcher will be influenced in his perception of the patient. It can 
also be adding complementary exams, or simply change in therapeutic adherence of different 
patients if they will continue to take a pill knowing it contains no active substance. Attrition 
bias is induced by exclusion of patients during the trial. Various situations can lead to a 
premature drop-out of patients, such as serious side effects, a lack of therapeutic adherence, 
the absence of the patient to follow-up visits, intake of forbidden medication, or the inclusion 
of patients not meeting inclusion criteria of the trial. At first sight it could seem logical not to 
take into account these patient in the analysis, because if they didn’t take the drug or didn’t 
follow the procedures described in the beginning it wouldn’t allow a proper result of the 
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efficacy of this drug. However, this loss of patients can create bias because their exclusion are 
usually not random but have a probability to depend on the treatment received and/or the 
evolution of the patient. If we exclude this patients, we might lose the comparability between 
the randomized groups. ‘Intention to treat’ analysis is a strategy for the analysis of RCT that 
compares patients in the groups to which they were originally assigned. This interpreted as 
including all patients, regardless of whether they actually satisfied the entry criteria, the 
treatment actually received, and subsequently withdrawal or deviation from the protocol. (24) 
For non-inferior trials ‘per protocole’, where only patients who received a strict conform 
treatment are presented in the study, should also be present before concluding on the results. 
Indeed, the drop-out is potentially more important with patients receiving the reference 
treatment, which would give results in favor of non-inferiority. Also specific bias concerning 
NI trials are related to the reference treatment used. It might not be administered correctly 
either in too week dosage or too slowly, and decrease its efficacy compared to the new 
treatment. The reference treatment can also be administered to patients that are less receptive 
to the therapy, or easily interrupted because of side effects, or simply not be the best treatment 
that actually exist at the moment. As a conclusion we can say that results can be biased if the 
reference treatment is not maximized. Its loss of efficacy can be due to selection bias, where 
the choice of patients is not in favor of the standard treatment or to follow-up bias if dosage 
and administration are not optimal. These conditions would then create proof of non-
inferiority, but the results of the clinical trial then should be discussed.  This is why a quality 
critical analysis using proper methodology and statistic of publications or clinical trial results 
is essential, because this is what with allow the physician to evaluate them and decide to use 
them or not during his/her clinical practice. 
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        4.2. NI margin determination : 
As we already defined what are NI margins, we will now focus on the concept of 
determination. It is emphasized and discussed in detail in the US Food and Drug 
Administration’s new draft guideline for NI trials. (25) The guideline was composed based on 
previous guidelines and methodological publications on NI trials (26) published since the 
1980s. Its focus is on showing indirect efficacy of the test drug compared with placebo. The 
method presented in the guidelines consists in determining two parameters M1 and M2. M1 is 
the statistical part, an objective parameter. It represents the effect of the active control 
compared with placebo, assumed present in the NI trial. . The statistical margin for the effect 
between the new drug and active control is set at the upper boundary of the 95% confidence 
interval of difference between placebo and active control. This value is obtained from relevant 
previous placebo-controlled trial of the active comparator. The best would be a meta-analysis 
of several placebo-controlled trials for a better estimate of the active comparator. The second 
step is to calculate M2 from M1 by choosing a certain amount of the effect to be preserved, 
called the clinical relevance margin. The draft FDA guideline implicitly recommends using 
a preserved-effect of 50% to determine M2. Choosing a higher percentage to be preserved 
results in a stricter or more conservative NI margin, meaning it is more difficult to conclude 
NI. For example, if it was concluded that it would be necessary for a test drug to preserve 
75% of a mortality effect, M2 would be 25% of M1. The formula to calculate M2 for a risk 
difference is : (1-preserved effects)*-(M1). For the determination of this margin, it is the 
choice of a clinician, which makes it subjective parameter. It is related to how much of the 
treatment effected is judged necessary, a consideration that may reflect the seriousness of the 
outcome, the benefit of the active comparator and the relative safety profiles of the test drug 
and comparator. This factor has considerable practical implications. For example, in large 
cardiovascular studies, it is unusual to seek retention of more than 50% of the effect of the 
 31 
 
control drug, even if this might be clinically reasonable, because doing so will usually cause 
the size of the study to become infeasible. (4) How investigators incorporate this clinical 
judgment remains unknown. These implicit clinical judgments might have been derived from 
clinical experience. However, these judgments remain subjective and different clinicians may 
propose contradicting judgments. That is why it is important to determine how this clinical 
judgment can be incorporated in the NI margin determination. 
 
        4.3. Interpretation of NI trials  
The inference from the result of an NI trial is based on the CI of the treatment difference 
between the new drug and its comparator. NI is inferred when the CI is at the correct side and 
excludes the NI margin. (27). To illustrates this, we categorized the possible CIs in NI trials 
into six types as presented in Figure 7: 
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[Figure 7: The confidence interval categories and non-inferiority interpretation. 
Horizontal line represents CI. The point-of-no difference is the point at which the estimate 
treatment difference between the new drug and comparator is neutral: zero for a difference in 
outcome or one for a ratio.(8)] 
Types A,B, and C can be defined as non-inferior , since their CI excludes the NI margin. In 
types D,E and F non-inferiority is not shown. Type C lies completely beyond the point-of-no 
difference line, would potentially demonstrate that the new drug is superior to its comparator. 
The switch from NI to superiority as we saw earlier is not excluded. But it is of course 
regulated by the Committee for Proprietary Product guidelines for example. (28) Type A also 
requires cautious interpretation. Although the lower limit lies above the NI margin, thereby 
showing NI, the upper limit lies below the point-of-no-difference, indicating that the new drug 
is actually statistically inferior to its comparator. However, the new drug can still be claimed 
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to be clinically non-inferior if the NI margin was determined on the basis of clinical 
relevance. 
 
        4.4. Sensitivity and constancy assumption 
Assay sensitivity is defined as the ability of an RCT to distinguish an effective treatment 
from an ineffective treatment. A drug is considered effective if it shows a significant 
treatment effect as compared with placebo. In a superiority trial, a significant difference 
between two treatments directly confirms assay sensitivity. In contrast, a NI does not directly 
show the efficacy of both drugs as compared with placebo. A NI could mean that both drugs 
were effective, but it could also mean that both drugs were ineffective. One possible solution 
is to include a placebo arm to confirm that both the new drug and the comparator drug are 
better than placebo. When designing NI trials, other options should be considered before 
making the decision to omit a placebo arm. For example to assign fewer people in the placebo 
group and shorten the duration of treatment, or to create an adaptive trial design in which 
placebo non-responders can be reallocated. Another related assumption that can’t be verified 
within the trial is the constancy assumption, which states that the effect of the active 
comparator versus placebo is present in the current trial. The determination of the NI margin 
directly relies on the size of the estimated treatment effect between the active comparator and 
the placebo. For the inference to be valid, it has to be assumed that this estimate is accurate 
for the trial at hand. And this can’t be assessed completely objectively. However, it can be 
supported by a proper meta-analysis and by a demonstration of similarity between the current 
trial and the trials used for setting the margin. The constancy assumption also relies on the 
absence of any influence from a number of factors, such as changes in standard of care, which 
are not easily verifiable. The question, therefore, remains as to whether the NI trials and 
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placebo-controlled trials were similar enough.  If a placebo are can’t be included, the authors 
should discuss how they have arrived at the conclusion that the trial has assay sensitivity and 
provide data-driven as well as clinical reasons for assuming that the constancy assumption is 
true. Without these assessments, the reader can’t reliably judge whether the conclusions from 
the trial are valid and relevant for treatment decisions.  In order to increase objectivity, more 
guidance is needed to improve adequate and consistent determination of clinically acceptable 
NI margins. 
 
5. Discussion. 
 
         5.1 Ethics 
One of the first reasons why some people want to ban NI trials is that they are considered 
unethical, since they do not offer any possible advantage to present on future patients, and 
they disregard patient’s interests in favor of commercial ones. They are believed to fail to 
meet the commitments of good clinical research: ‘Ask an important question, and answer it 
reliably’. (29) But we clearly explained previously that even when a trial is set out to prove 
that a new drug has additional benefit a part of the study still has to assess non-inferiority of 
the primary outcome. Although one could claim that in any trial a superiority aim should be 
included, non-inferiority for other outcomes remains an important additional goal. Patients 
can be involved in clinical trials only if there is a reasonable potential advantage, for them or 
for future patients. The advantage could be increased efficacy, decreased toxicity, different 
toxic profiles, better compliance, longer duration of action, and other sizable factors. NI trials 
also allow patients and doctors to have the possibility of choosing among different drugs. This 
has a particular interest for patients who do not respond to standard treatment. In this case 
non-inferiority trials offer a very useful alternative. (4) 
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        5.2 Methodological argument 
 
As we saw in the previous section the determination factors in determining NI margins are 
assay sensitivity and constancy assumption which relies heavily on clinical evidence. The 
second argument in favor to ban NI trials is the methodological argument. The fact that a NI 
trial can’t be objectively determined. It is true that interpretation and inference of NI trials are 
complicated, partly because of the incompleteness of the information. A research in PubMed 
in February 2009  that randomly selected 300 NI trial publication showed that <50% of the 
trials reported the method used to determine the NI margin, and <10% of the trials stated that 
the NI margin was a priori justified on the basis of clinical margin. They also found out that  
>8% were interpreted incorrectly, and <10% of them included placebo arms to ensure assay 
sensitivity or discuss the validity of constancy assumption. (3) The International Conference 
on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human 
Use, the European Medicines Agency, and the most recent draft of US Food and Drug 
Administration guidelines emphasize that determination of the NI margin should be based on 
both clinical and statistical margins. Meanwhile, it is hard to determine from the literature 
whether the trials actually followed the guidelines. So far, most of the efforts to overcome the 
methodological challenges in NI trials have concentrated on this issue, and better regulation is 
expected. Furthermore, even though the use of ‘outdated’ placebo-controlled trials data might 
not be avoidable, increasing knowledge on the evidence base of the drugs and the disease 
itself, the size of the estimated treatment effect between the active comparator and the placebo 
can be more accurately defined. 
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         5.3. Subjectivity 
 
Efforts to reduce subjectivity in clinical testing have been studied more extensively. They 
include the patient’s perception that might have an importance in the results and has to be 
taken into account, and use of a systematic scoring system in defining a minimal clinically 
importance difference. Most, if not all of the regulations and guidelines focus on statistical 
methods. Unfortunately, the interpretation and reporting of trial results from the perspective 
of clinical importance has not received similar emphasis. This imbalance promotes the 
historical tendency to consider clinical trials results that are statistically significant as also 
clinically important, and conversely, those with statistically insignificant results as being 
clinically unimportant. (30)  
The strongly criticized subjectivity in clinical judgment, this part that can’t be defined in a 
statistical matter applicable in any trial also might prevent the drugs tested to gradually move 
to less effective treatments.  In other words, perception of the investigators plays an important 
role in preventing biocreep. This degradation of the efficacy of the investigational treatment is 
theoretically not a mistake on the paper, only an outside judgment can prevent this cyclical 
phenomenon.(31)  
 
           5.4 Same drug, different results 
One of the main problems encountered while using NI trial is the variability and results. Let’s 
take the example of a NI trial designed to study apixan, a specific factor Xa inhibitor that may 
provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use 
than low-molecular-weight heparins such as enoxaparin. The study plan was based on the 
hypothesis that apixaban would be non-inferior to enoxaparin with respect to the primary 
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efficacy outcome which includes incidence in all VTE and death from any cause, with the use 
of a prespecified NI margin in which the upper limit of the 95% confidence interval for 
relative risk did not exceed 1,25 and for absolute risk 5,6 percentage points. Both criteria had 
to be met to establish non-inferiority. Results showed 9% incidence in primary outcome 
compared to 8,8% with enoxaparin. The criteria were not met because the relative risk 
interval was from 0,78 to 1.32, although the absolute risk was <5,6. The reason why the trial 
was expecting better outcome is that the results were expected to be much different for 
enoxaparin. Indeed, the assumptions made in establishing the criteria for NI and calculating 
the sample size were based on previous clinical trials. The judgment of outcome events in this 
trial was consistent with the trial were about 16% in the control group given enoxaparin. In 
the trial, the 8,8% incidence of the primary efficacy outcome in patients treated with 
enoxaparin was only 55% of the predicted rate. This made it difficult to meet the prespecified 
criteria for non-inferiority. (32) This is the case in many other studies on thromboprophylactic 
drugs and clinical trial as a whole. 
 
Clinical trials are a very expensive undertaking, consuming a great deal of time and resources. 
To compare the efficacy of different drugs, dosages, surgeries or combinations of these 
treatments can cost over $5OO million and take many years, so it is of great importance that 
the design of the clinical trial gives a good chance of successfully demonstrating a treatment 
effect.  Meanwhile, the benefit of the patient is and should always be the main goal, before the 
success of a drug development. This is why regulators need to have attention for unproved 
claims of additional benefit in NI trials to avoid misuse of the results of NI trials as a cover for 
unethical marketing. Last but not least we can say that there is still ample room to improve the 
determination of the NI trials and especially the NI margin. To support it, dialogue with 
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regulators to solve specific issues in NI trials could be improved, for example through 
scientific advice. 
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